Filing Details
- Accession Number:
- 0001209191-15-005649
- Form Type:
- 4/A
- Zero Holdings:
- No
- Publication Time:
- 2015-01-21 21:09:38
- Reporting Period:
- 2015-01-15
- Filing Date:
- 2015-01-21
- Accepted Time:
- 2015-01-21 21:09:38
- Original Submission Date:
- 2015-01-20
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1466301 | Clovis Oncology Inc. | CLVS | Pharmaceutical Preparations (2834) | 900475355 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1374539 | R Andrew Allen | C/O Clovis Oncology, Inc. 2525 28Th Street, Suite 100 Boulder CO 80301 | See Remarks | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2015-01-15 | 300 | $65.00 | 181,619 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2015-01-16 | 30,524 | $65.27 | 151,095 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2015-01-16 | 49,176 | $66.26 | 101,919 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2014.
- The price reported reflects the weighted average sale price. The shares of Common Stock were purchased in multiple transactions at prices ranging from $65.00 to $65.94, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- The price reported reflects the weighted average sale price. The shares of Common Stock were purchased in multiple transactions at prices ranging from $66.01 to $67.00, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Billionaire Hedge Funds
